EKRA Compliance: What Treatment Programs, Labs, and Marketers Must Know

The Eliminating Kickbacks in Recovery Act (EKRA), enacted in 2018 as part of the SUPPORT Act, is the compliance statute most often misread in behavioral health. Two features make it different from everything providers were trained on.

**EKRA applies regardless of payer.** The Anti-Kickback Statute reaches items and services reimbursable by federal health care programs. EKRA reaches private pay and commercial insurance too. A cash-pay treatment program with no Medicaid or Medicare business is fully within scope.

**EKRA is a criminal statute with individual exposure.** Penalties run up to $200,000 in fines and up to 10 years imprisonment per occurrence. Executives, marketing staff, and owners can be charged personally.

Who EKRA covers

EKRA applies to three categories:

- **Recovery homes** — facilities providing shared housing and recovery support services - **Clinical treatment facilities** — facilities providing SUD detoxification, treatment, or care on an inpatient, outpatient, or residential basis - **Laboratories** — broadly defined, which is why toxicology arrangements draw so much enforcement attention

What the statute prohibits

Knowingly and willfully soliciting, receiving, paying, or offering any remuneration, directly or indirectly, in cash or in kind, in return for referring a patient to a recovery home, clinical treatment facility, or laboratory — or in exchange for an individual using the services of one.

"Remuneration" is broad: cash, bonuses, free rent, discounted services, staffing, travel, meals, and equity arrangements can all qualify.

The employee compensation trap

This is where well-run organizations most often get exposed.

The Anti-Kickback Statute has a bona fide employee safe harbor that broadly protects payments to W-2 employees. **EKRA's employee exception is narrower.** It does not protect compensation that varies based on:

- the number of individuals referred - the number of tests or procedures performed - the amount billed to or received from health care benefit programs

In practice this means commission structures, per-admission bonuses, and volume-based incentives for admissions, outreach, or marketing staff are high risk under EKRA **even when the person is a W-2 employee and even when no federal dollars are involved**. Courts have reached that conclusion, and prosecutors have acted on it.

Safer structures include fixed salary, bonuses tied to non-referral metrics such as quality measures, documentation timeliness, client satisfaction, retention in treatment, or overall organizational performance not traceable to individual referral volume.

High-risk arrangements to review now

- Marketing or call center contracts paid per admission, per lead conversion, or as a percentage of revenue - Toxicology or lab arrangements where compensation tracks specimen volume - Payments, rent subsidies, or in-kind support between treatment providers and sober living or recovery residences - Free or below-market staffing, space, or services provided to a referral source - Equity or profit-sharing given to individuals in a position to refer - "Consulting" or "medical director" agreements without documented duties, deliverables, or fair market value support - Patient inducements: waived copays as a routine practice, free rent, gift cards, or paid travel to enter treatment

EKRA and AKS compared

| | Anti-Kickback Statute | EKRA | |---|---|---| | Payers covered | Federal health care programs | All payers, including private and self-pay | | Entities | Broad health care | Recovery homes, clinical treatment facilities, labs | | Employee compensation | Broad bona fide employee safe harbor | Narrow — cannot vary with referral or test volume | | Penalties | Criminal and civil, exclusion | Up to $200,000 and 10 years per occurrence |

Complying with one does not mean complying with the other. Arrangements must be tested against both, plus state patient brokering laws, which in several states are stricter than either.

Building an EKRA compliance program

1. **Inventory every arrangement** that touches a referral: marketing vendors, call centers, housing partners, labs, medical directors, consultants, and internal compensation plans. 2. **Restructure volume-based pay** for anyone in a position to influence referrals. 3. **Document fair market value** for every payment to a potential referral source, with a written analysis, not an assumption. 4. **Require legal review before signing** any marketing, lab, housing, or referral-adjacent agreement. 5. **Document clinical justification** for placements and referrals in the client record. 6. **Train** admissions, marketing, clinical, and leadership staff, and repeat it annually. 7. **Audit** referral patterns, marketing spend, and lab utilization for the trend lines that enforcement follows. 8. **Provide a confidential reporting channel** with a real non-retaliation policy, and act on what comes through it.

The practical test

Before signing anything, ask: does any part of this payment go up when more clients are referred, admitted, or tested? If the answer is yes, assume EKRA risk and get counsel involved before, not after.

*This article is for educational purposes only and is not legal advice. Consult qualified health care counsel about your specific arrangements.*